Alembic Pharmaceuticals gets USFDA nod for Fenofibric Acid Delayed-Release Capsules

15 May 2017 Evaluate

Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fenofibric Acid Delayed-Release Capsules, 45 mg and 135 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Trilipix Delayed-Release Capsules, 45 mg and 135 mg, of Abbvie Inc. Fenofibric Acid Delayed-Release Capsules have an estimated market size of $93 million for twelve months ending December 2016, according to IMS.

Fenofibric Acid Delayed- Release Capsules are indicated as an adjunctive therapy to diet to reduce triglycerides (TG) in patients with severe hypertriglyceridemia and to reduce elevated LDL-C, total cholesterol (Total-C), TG and Apo B, and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia.

Alembic now has a total of 56 ANDA approvals (50 final approvals and 6 tentative approvals) from USFDA.


Alembic Pharma Share Price

937.00 -9.30 (-0.98%)
28-May-2024 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1464.85
Dr. Reddys Lab 5955.65
Cipla 1477.15
Zydus Lifesciences 1050.35
Lupin 1603.55
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.